Comparative risk of liver aminotransferase levels >200 U/L among users of different nucleoside reverse-transcriptase inhibitor (NRTI) combinations (Model A), antiretroviral classes (Model B), and antiretroviral regimens (Model C). ^a“Other” includes regimens with <2 NRTIs or alternative NRTI combinations than those listed. ^bEach model adjusted for baseline alanine aminotransferase >40 U/L, calendar year of antiretroviral therapy initiation, and data source. ^cOther refers to regimens with none or >1 of the listed antiretroviral class. ABC, abacavir; ATV/r, boosted atazanvir; DRV/r, boosted darunavir; EFV, efavirenz; FTC, emtricitabine; INSTI, integrase inhibitor; LPV/r, boosted lopinavir; PI, protease inhibitor; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine.